Literature DB >> 8096074

Initiation of bladder cancer may involve deletion of a tumour-suppressor gene on chromosome 9.

P Cairns1, M E Shaw, M A Knowles.   

Abstract

Although many genetic lesions including suppressor gene inactivation have been identified in sporadic tumours, the identity of the common initiating or early genetic events in most cases remains obscure. We have analysed tumour and leucocyte DNA from a series of 252 primary human bladder tumours of all grades and stages for deletions of chromosome 9. Probes from four polymorphic loci were used to detect loss of heterozygosity (LOH) in tumour specimens. Fifty-nine per cent of tumours from patients informative at one or more of these loci showed LOH. A comparison of LOH for markers on 9p and 9q indicated that proximal 9p or 9q is the likely site for a candidate bladder tumour-suppressor gene. Most strikingly, LOH was observed not only in tumours of high grade or stage but also in > 50% of grade 1 and 2 superficial (pTa) tumours. This is the first change to be identified at significant frequency in such tumours. Inactivation of a tumour-suppressor gene on chromosome 9 may therefore be an early genetic event in the development of bladder cancer.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8096074

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  32 in total

Review 1.  The role of fluorescence in situ hybridization technologies in molecular diagnostics and disease management.

Authors:  W King; J Proffitt; L Morrison; J Piper; D Lane; S Seelig
Journal:  Mol Diagn       Date:  2000-12

2.  The value of the preoperative FISH test in unscreened bladder cancer patients with TUR indications.

Authors:  S V Petrov; K A Malkhasyan; M Yu Ulyanin; E F Abdrakhmanov; R Sh Khasanov
Journal:  Pathol Oncol Res       Date:  2012-06-23       Impact factor: 3.201

Review 3.  Molecular genesis of non-muscle-invasive urothelial carcinoma (NMIUC).

Authors:  Courtney Pollard; Steven C Smith; Dan Theodorescu
Journal:  Expert Rev Mol Med       Date:  2010-03-25       Impact factor: 5.600

Review 4.  Genetics of bladder cancer.

Authors:  K K Saran; D Gould; C J Godec; R S Verma
Journal:  J Mol Med (Berl)       Date:  1996-08       Impact factor: 4.599

5.  Mammalian target of rapamycin (mTOR) regulates cellular proliferation and tumor growth in urothelial carcinoma.

Authors:  Donna E Hansel; Eric Platt; Mohammed Orloff; Jyoti Harwalker; Swathi Sethu; Jessica L Hicks; Angelo De Marzo; Roxanne E Steinle; Eric D Hsi; Dan Theodorescu; Christina B Ching; Charis Eng
Journal:  Am J Pathol       Date:  2010-04-15       Impact factor: 4.307

Review 6.  Molecular genetics of bladder cancer: Emerging mechanisms of tumor initiation and progression.

Authors:  David J McConkey; Sangkyou Lee; Woonyoung Choi; Mai Tran; Tadeusz Majewski; Sooyong Lee; Arlene Siefker-Radtke; Colin Dinney; Bogdan Czerniak
Journal:  Urol Oncol       Date:  2010 Jul-Aug       Impact factor: 3.498

7.  Analysis of the copy number profiles of several tumor samples from the same patient reveals the successive steps in tumorigenesis.

Authors:  Eric Letouzé; Yves Allory; Marc A Bollet; François Radvanyi; Frédéric Guyon
Journal:  Genome Biol       Date:  2010-07-22       Impact factor: 13.583

Review 8.  Molecular pathogenesis of bladder cancer.

Authors:  Margaret A Knowles
Journal:  Int J Clin Oncol       Date:  2008-08-15       Impact factor: 3.402

9.  The expression of PAX5, p53 immunohistochemistry and p53 mutation analysis in superficial bladder carcinoma tissue. Correlation with pathological findings and clinical outcome.

Authors:  M Babjuk; V Soukup; J Mares; J Dusková; Z Sedlácek; M Trková; L Pecen; J Dvorácek; T Hanus; R Kocvara; J Novák; C Povýsil
Journal:  Int Urol Nephrol       Date:  2002       Impact factor: 2.370

Review 10.  Phosphatidylinositol 3-kinase (PI3K) pathway activation in bladder cancer.

Authors:  Margaret A Knowles; Fiona M Platt; Rebecca L Ross; Carolyn D Hurst
Journal:  Cancer Metastasis Rev       Date:  2009-12       Impact factor: 9.264

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.